Glow-in-the-dark animal captured on camera for first time
A photographer from Down Under has become the first person to capture a photo of a glowing marsupial in the wild.
Aussie photographer Ben Alldridge submitted a photo as part of the 2025 Beaker Street Science Photography Prize. The photo was of a wild Eastern quoll, which is carnivorous marsupial that's native to Tasmania and exhibits biofluorescence.
Using invisible ultraviolet light, Alldridge captured the mammal glowing in the dark, and his photo is considered the first photographic evidence of a quoll exhibiting biofluorescence in its natural habitat, people.com reported.
'Where their fur is normally fawn or black, under certain wavelengths of light, they exhibit a process referred to as biofluorescence — like nature's version of a white shirt glowing at a disco,' Alldridge said, per the Daily Mail.
Smithsonian Magazine reported that several mammals across the globe, many of them nocturnal, are known to exhibit this phenomenon, including polar bears, moles, zebras, wombats, armadillo and more. Non-mammals such as corals, insects, spiders, fish, amphibians, reptiles and birds also exhibit the phenomenon, although the exact biological purpose of biofluorescence is still unknown.
Alldridge said he hopes his photos and studies into biofluorescence will help solve the mystery surrounding it.
Recommended video
'I'd say it's likely a messaging or identifying system similar to our fingerprints, but that is wild speculation at best,' he said, per the Daily Mail. 'For now, we will just say they like to party.'
Alldridge's photography will be considered as part of the ongoing research.
'The amount of light we waste illuminating space — both physical and now literal — is ridiculous, and in many cases is counterproductive to why the lights are installed to begin with,' Alldridge said.
Alldridge's photo is one of 12 finalist images to be exhibited at the Tasmanian Museum and Art Gallery from Aug. 6-31, as part of the Beaker Street Festival.
Experts puzzled as chimps reportedly getting extra cheeky with grass fad
Pets can stave off dementia for people over 50 living alone: Study
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Dead scientist's 'time capsule' in vault key to resurrecting Aussie species
A sprawling collection of 3,500 specimens held in the vault of an Australian museum could provide an insight into a natural world that was largely destroyed last century, and help resurrect species that have disappeared from the area. Each tiny glass vial contains a trapdoor spider, and all of them were collected by one woman. Many of the species are now locally extinct from the sprawling Wheatbelt region that surrounds Perth. Spider expert Dr Mark Harvey, who is leading a project at Western Australian Museum, to digitise the collection, describes it as a 'time capsule'. By understanding which spiders were present at any given location, scientists are able to form a picture of what the wider ecosystem once looked like before it was replaced with crops of wheat and canola, or grassy paddocks for raising livestock. For instance, the shield-backed trapdoor spider (Idiosoma nigrum) preferred to live in woodland that was fairly flat and not very dense. And this same specific type of landscape would have also been home to many of the small mammals that are now locally extinct. When the shield-backed trapdoor spider was collected in the 1950s, the species was considered abundant on the Wheatbelt. Today it survives in a few small fragments of bushland that were retained in the region. 'Once they've been lost from an area, because the native habitat is a patchwork, and no longer connected, they can't move from one place to another to recolonise,' Harvey said. 'Trapdoor spiders are very bad at that at the best of times, because the spiderlings come out of the mother's burrow, they might only walk one, two or three metres before they start their own. And that's where they spend the rest of their lives — so they don't disperse like other animals do.' Related: Major weather event prompts behavioural change in Wheatbelt wildlife A healthy ecosystem in southwest Australia has 10 to 15 species of trapdoor spider, so when researchers return to an area and only find two or three, they know localised extinctions have occurred and the landscape has been degraded. Woman watched as entire region transformed The spiders were all collected by Dr Barbara York Main, known as Australia's spider lady, who died in 2019. She was born in 1929 and grew up in the Wheatbelt, giving her a front seat to watch the dramatic change that occurred over her lifetime. The collection contains a number of species that are yet to be officially described or named by scientists. By digitising her collection, the data will become available to scientists around the world, and the general public through the Atlas of Living Australia and WA's Dandjoo statewide biodiversity data platform. In 2025, the impact of habitat destruction on native species is well-known, but several species of trapdoor spider are barely surviving the ongoing threats to their range. The Euoplos dignitas in Queensland's Brigalow Belt was only identified in 2023, and it's already endangered. It survives in a heavily fragmented 1850 square kilometre area that successive state governments have allowed to be cleared for cattle grazing and crops. More incredible museum stories Decades-old Aussie museum display discovered to be entirely new species New Aussie predatory species discovered inside museum package Discovery on museum shelves hints at presence of 250 unknown scorpion species Spider DNA could help resurrect species Harvey is hopeful that in the future, as DNA technology improves, it could be possible to resurrect trapdoor spiders using genetic material from the collection. But even if de-extinction is not possible, it might be possible to help fragmented populations of spiders, that have become genetically compromised as their numbers have shrunk. 'We could use those specimens taken from when they were fairly widespread species across the landscape, look at its genetic variation, and then compare it to the modern examples we might find now. When the populations have shrunk in size, and we can see what sort of genetic variation is lacking,' Harvey said. 'We might be able to do something about it with gene splicing.' Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.
CBS News
13 hours ago
- CBS News
Humans triumph over AI at annual math Olympiad, but the machines are catching up
Sydney — Humans beat generative AI models made by Google and OpenAI at a top international mathematics competition, but the programs reached gold-level scores for the first time, and the rate at which they are improving may be cause for some human introspection. Neither of the AI models scored full marks — unlike five young people at the International Mathematical Olympiad (IMO), a prestigious annual competition where participants must be under 20 years old. Google said Monday that an advanced version of its Gemini chatbot had solved five out of the six math problems set at the IMO, held in Australia's Queensland this month. "We can confirm that Google DeepMind has reached the much-desired milestone, earning 35 out of a possible 42 points - a gold medal score," the U.S. tech giant cited IMO president Gregor Dolinar as saying. "Their solutions were astonishing in many respects. IMO graders found them to be clear, precise and most of them easy to follow." Around 10% of human contestants won gold-level medals, and five received perfect scores of 42 points. U.S. ChatGPT maker OpenAI said its experimental reasoning model had also scored a gold-level 35 points on the test. The result "achieved a longstanding grand challenge in AI" at "the world's most prestigious math competition," OpenAI researcher Alexander Wei said in a social media post. "We evaluated our models on the 2025 IMO problems under the same rules as human contestants," he said. "For each problem, three former IMO medalists independently graded the model's submitted proof." Google achieved a silver-medal score at last year's IMO in the city of Bath, in southwest England, solving four of the six problems. That took two to three days of computation — far longer than this year, when its Gemini model solved the problems within the 4.5-hour time limit, it said. The IMO said tech companies had "privately tested closed-source AI models on this year's problems," the same ones faced by 641 competing students from 112 countries. "It is very exciting to see progress in the mathematical capabilities of AI models," said IMO president Dolinar. Contest organizers could not verify how much computing power had been used by the AI models or whether there had been human involvement, he noted. In an interview with CBS' 60 Minutes earlier this year, one of Google's leading AI researchers predicted that within just five to 10 years, computers would be made that have human-level cognitive abilities — a landmark known as "artificial general intelligence." Google DeepMind CEO Demis Hassabis predicted that AI technology was on track to understand the world in nuanced ways, and to not only solve important problems, but even to develop a sense of imagination, within a decade, thanks to an increase in investment. "It's moving incredibly fast," Hassabis said. "I think we are on some kind of exponential curve of improvement. Of course, the success of the field in the last few years has attracted even more attention, more resources, more talent. So that's adding to the, to this exponential progress."
Yahoo
17 hours ago
- Yahoo
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. 'Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,' said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. 'We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.' About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie Fields Precision AQ (Formerly Stern IR) E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – Twitter – Linked In – –
